Cargando…

Adult‐onset Still's disease following mRNA‐1273 Moderna COVID‐19 vaccination: A case report

A 57‐year‐old woman who was inoculated with the second dose of the mRNA‐1273 Moderna COVID‐19 vaccine and then developed adult‐onset still’s disease as a result.[Image: see text]

Detalles Bibliográficos
Autores principales:	Iwata, Masahiro, Ogawa, Tatsuya, Anju, Keisuke, Okiyama, Naoko, Nomura, Toshifumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874601/ http://dx.doi.org/10.1002/cia2.12281

Ejemplares similares

Central retinal artery occlusion after Moderna mRNA-1273 vaccination
por: Chow, Sin Yu, et al.
Publicado: (2022)

New‐onset vitiligo following mRNA‐1273 (Moderna) COVID‐19 vaccination
por: Kaminetsky, Joshua, et al.
Publicado: (2021)

Bullous Pemphigoid Following the Moderna mRNA-1273 Vaccine
por: Desai, Amar D, et al.
Publicado: (2022)

De novo vasculitis after mRNA-1273 (Moderna) vaccination
por: Anderegg, Manuel A., et al.
Publicado: (2021)

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine
por: Wu, Kai, et al.
Publicado: (2021)

Immune Thrombocytopenia Following Booster Dose of the Moderna mRNA-1273 Vaccine
por: Breetz, Katherine A, et al.
Publicado: (2022)

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Purpuric Rash and Thrombocytopenia After the mRNA-1273 (Moderna) COVID-19 Vaccine
por: Malayala, Srikrishna V, et al.
Publicado: (2021)

Pityriasis rosea after Moderna mRNA‐1273 vaccine: A case series
por: Martora, Fabrizio, et al.
Publicado: (2021)

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
por: Widge, Alicia T., et al.
Publicado: (2020)

Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients
por: Hall, Victoria G., et al.
Publicado: (2021)

Re: Heterologous Gam-COVID-Vac (Sputnik V)/mRNA-1273 (Moderna) vaccination
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

COVID‐19 mRNA‐1273 vaccine induces production of vaccine‐induced immune thrombotic thrombocytopenia antibodies
por: Padmanabhan, Anand, et al.
Publicado: (2022)

Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2
por: Blumenthal, Kimberly G., et al.
Publicado: (2021)

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
por: Normark, Johan, et al.
Publicado: (2021)

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
por: Pajon, Rolando, et al.
Publicado: (2022)

Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Herpes zoster reactivation after mRNA-1273 (Moderna) SARS-CoV-2 vaccination
por: Channa, Leelakrishna, et al.
Publicado: (2021)

Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine
por: Holzworth, Amy, et al.
Publicado: (2021)

Bell's palsy as a possible complication of mRNA-1273 (Moderna) vaccine against COVID-19
por: Poudel, Sujan, et al.
Publicado: (2022)

Heterologous Gam-COVID-Vac (Sputnik V)/mRNA-1273 (Moderna) vaccination: Author's response
por: Pereson, Matías J., et al.
Publicado: (2022)

Acquired Angioedema Acute Attack After Administration of the Moderna COVID-19 (mRNA-1273) Vaccine
por: Graziani, Alessandro, et al.
Publicado: (2023)

2336. General Safety Profile of mRNA-1273 (Moderna COVID-19 Vaccine) in the Elderly Population
por: Anteyi, Kate, et al.
Publicado: (2023)

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
por: Doria-Rose, Nicole, et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination
por: Shen, Xiaoying, et al.
Publicado: (2022)

Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge
por: Baden, Lindsey R., et al.
Publicado: (2021)

Acute tolerance of Moderna mRNA-1273 vaccine against COVID-19 in patients with cancer treated with radiotherapy
por: Scoccianti, Silvia, et al.
Publicado: (2021)

Guillain‐Barré syndrome after mRNA‐1273 (Moderna) COVID‐19 vaccination: A case report
por: Anjum, Zauraiz, et al.
Publicado: (2022)

Paucisymptomatic COVID-19 in lung transplant recipient following two doses of mRNA-1273 (Moderna) vaccine
por: Marinelli, Tina, et al.
Publicado: (2021)

Cutaneous Sarcoidosis-like Eruption Following Second Dose of Moderna mRNA-1273 Vaccine: Case or Relationship?
por: Cazzato, Gerardo, et al.
Publicado: (2023)

2357. Descriptive Analyses of mRNA-1273 (Moderna COVID-19 vaccine) Spontaneous Reports by Geographic Regions
por: Emile-Backer, Magalie, et al.
Publicado: (2023)

Effectiveness of the mRNA-1273 Vaccine during a SARS-CoV-2 Delta Outbreak in a Prison
por: Chin, Elizabeth T., et al.
Publicado: (2021)

Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions
por: Haq, Hannah N., et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron BA.1, BA.4, and BA.5 by primary ChAdOx1 nCoV-19, mRNA-1273, MVC-COV1901 and booster mRNA-1273 vaccination
por: Liu, Yuag-Meng, et al.
Publicado: (2022)

New-onset chilblains in close temporal association to mRNA-1273 vaccination
por: Kha, Connie, et al.
Publicado: (2021)

Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report
por: Kong, Joyce, et al.
Publicado: (2021)

De-novo Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Following the mRNA-1273 (Moderna) Vaccine for COVID-19
por: Feghali, Elio Junior, et al.
Publicado: (2021)

Atrial fibrillation as a precursor of mRNA-1273 SARS-CoV-2 vaccine-induced pericarditis
por: Scheuermeyer, Frank X., et al.
Publicado: (2022)

Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine
por: Islam, Nazmul, et al.
Publicado: (2022)

Two possible etiologies of Guillain-Barré syndrome: mRNA-1273 (Moderna) vaccination and scrub typhus: A case report
por: Hwang, Byoung Wook, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g38tfu3qrbjelem9iope1e1bnc